Roth Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by Roth Capital in a report issued on Monday,Benzinga reports. They currently have a $12.00 target price on the stock. Roth Capital’s price target would suggest a potential upside of 143.70% from the stock’s current price.

COYA has been the subject of a number of other research reports. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Price Performance

COYA stock traded up $0.05 during midday trading on Monday, reaching $4.92. 55,156 shares of the stock were exchanged, compared to its average volume of 188,206. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company has a fifty day moving average price of $4.90 and a 200 day moving average price of $4.67. The stock has a market capitalization of $115.52 million, a PE ratio of -4.60 and a beta of 0.61.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts anticipate that Coya Therapeutics will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics in the third quarter valued at approximately $28,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Coya Therapeutics during the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at $66,000. Oppenheimer & Co. Inc. bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at $81,000. Finally, AXQ Capital LP acquired a new position in shares of Coya Therapeutics during the 2nd quarter valued at $116,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.